TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-18

Archived explainer. For the current picture see today's RYTM page.

Why Is RHYTHM PHARMACEUTICA (RYTM) Stock Up Today?

By the Top Tier Newswire AI Desk · November 18, 2026 at 12:14 AM ET · reviewed against 8 wire stories

RHYTHM PHARMACEUTICA (RYTM) is up +8.49% in the latest session. Our newswire has captured 8 stories on RYTM across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Rhythm Pharmaceuticals (RYTM) shares rose 8.49% to $116.61, driven by positive two-year results from the Phase 3 TRANSCEND trial and reports of acquisition interest from major pharmaceutical companies. The stock’s movement reflects a combination of clinical validation for its lead drug, setmelanotide, and heightened speculation regarding a potential merger.

What Happened

The company presented new data at ObesityWeek 2026, showing that continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity. Analysts at Canaccord characterized the obesity data as incrementally positive. Concurrently, market reports indicated that Eli Lilly submitted a rival bid near $150 per share, including a contingent value right. This development followed earlier reports that AstraZeneca proposed a $10 billion acquisition of the company. The convergence of strong clinical evidence and competing takeover offers created significant momentum in the stock price during the session.

What The Data Shows

Rhythm Pharmaceuticals has a market capitalization of $8.0 billion and remains unprofitable, with a trailing twelve-month EPS of -2.91 and a net margin of -69.0%. Revenue grew 61.0% over the same period. The stock carries a beta of 2.14, indicating higher volatility than the broader market. Over the last 8 sessions, the stock moved 3.9%, rising from $112.28 to $116.61. The 52-week range spans from $74.50 to $122.20. Recent insider activity includes two sales totaling $11.8 million, with the most recent transaction by President and CEO David P. Meeker on September 14, 2026. The 30-day average sentiment score is 60 out of 100, improving to 66 out of 100 over the last seven days.

What To Watch

Investors will monitor the outcome of the acquisition talks between Rhythm Pharmaceuticals and its potential suitors. The company’s ability to sustain revenue growth while managing its negative net margin will also be key factors in the near term.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

RYTM by the numbers

Last: $116.61Session: +8.49%7 sessions: +4.48%Coverage: 8 stories / 5 sourcesAI sentiment: 66/100 (bullish)Mkt cap: $8.0B52w: $74.50 to $122.20
RYTM · Nov 18 session (5-min) · +2.05% vs prior close · updated 8:53 PM ET
$115$118$122prev close $116.61$119.007:00 AM9:48 AM12:37 PM3:26 PM6:15 PM7:00 AM · $117.207:05 AM · $117.008:20 AM · $116.258:25 AM · $116.258:30 AM · $116.158:40 AM · $115.508:45 AM · $115.108:50 AM · $115.308:55 AM · $115.759:30 AM · $115.769:35 AM · $115.989:40 AM · $115.829:45 AM · $115.399:50 AM · $115.339:55 AM · $116.9910:00 AM · $115.6810:05 AM · $116.3410:10 AM · $117.2810:15 AM · $117.3610:20 AM · $117.7610:25 AM · $117.6310:30 AM · $117.5810:35 AM · $117.0010:40 AM · $116.4610:45 AM · $116.7410:50 AM · $116.4310:55 AM · $117.0011:00 AM · $117.0311:05 AM · $116.3711:10 AM · $116.7011:15 AM · $116.2811:20 AM · $116.7011:25 AM · $116.9211:30 AM · $117.0211:35 AM · $116.9511:40 AM · $117.3311:45 AM · $117.1711:50 AM · $117.1911:55 AM · $117.1912:00 PM · $118.1312:05 PM · $118.0212:10 PM · $118.2212:15 PM · $118.9412:20 PM · $119.0212:25 PM · $119.8112:30 PM · $119.6512:35 PM · $119.4312:40 PM · $119.0212:45 PM · $118.8612:50 PM · $118.8812:55 PM · $118.801:00 PM · $118.821:05 PM · $118.651:10 PM · $118.891:15 PM · $118.701:20 PM · $119.271:25 PM · $119.571:30 PM · $119.671:35 PM · $119.881:40 PM · $120.511:45 PM · $120.411:50 PM · $121.221:55 PM · $121.162:00 PM · $120.492:05 PM · $120.282:10 PM · $120.752:15 PM · $120.792:20 PM · $120.692:25 PM · $120.592:30 PM · $119.952:35 PM · $119.992:40 PM · $119.522:45 PM · $118.902:50 PM · $119.142:55 PM · $118.923:00 PM · $119.293:05 PM · $119.113:10 PM · $118.693:15 PM · $118.973:20 PM · $118.723:25 PM · $118.843:30 PM · $118.913:35 PM · $119.013:40 PM · $119.003:45 PM · $118.963:50 PM · $120.113:55 PM · $119.154:00 PM · $119.044:20 PM · $119.044:50 PM · $119.045:20 PM · $119.046:15 PM · $119.00
AI sentiment, last 36h · averaged over 8 stories · 66/100 bullish
AI sentiment 66/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishGlobeNewswire · sentiment 64 · Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026GlobeNewswire · 64Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026Business Insider · sentiment 63 · Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026Business Insider · 63Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026The Fly · sentiment 74 · Rhythm: Two-year results from Phase 3 trial showed sustained BMI reductionsThe Fly · 74Rhythm: Two-year results from Phase 3 trial showed sustained BMI reductionsSeeking Alpha · sentiment 64 · Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVRSeeking Alpha · 64Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVRGuruFocus · sentiment 64 · Eli Lilly Eyes Rhythm Pharmaceuticals (RYTM) in Obesity Sector Acquisition TalksGuruFocus · 64Eli Lilly Eyes Rhythm Pharmaceuticals (RYTM) in Obesity Sector Acquisition TalksGuruFocus · sentiment 63 · Rhythm Pharmaceuticals (RYTM) Highlights Setmelanotide Efficacy in Acquired Hypothalamic Obesity at ObesityWeek 2026GuruFocus · 63Rhythm Pharmaceuticals (RYTM) Highlights Setmelanotide Efficacy in Acquired Hypothalamic …The Fly · sentiment 58 · Canaccord views Rhythm obesity data as ‘incrementally positive’The Fly · 58Canaccord views Rhythm obesity data as ‘incrementally positive’GuruFocus · sentiment 74 · Rhythm Pharmaceuticals (RYTM) Shares Rise on Positive Two-Year TRANSCEND Trial ResultsGuruFocus · 74Rhythm Pharmaceuticals (RYTM) Shares Rise on Positive Two-Year TRANSCEND Trial Results
2d agoGuruFocusBULLISH 74Product/PR

Rhythm Pharmaceuticals (RYTM) Shares Rise on Positive Two-Year TRANSCEND Trial Results

2d agoThe FlyBULLISH 58Analyst

Canaccord views Rhythm obesity data as ‘incrementally positive’

2d agoGuruFocusBULLISH 63Product/PR

Rhythm Pharmaceuticals (RYTM) Highlights Setmelanotide Efficacy in Acquired Hypothalamic Obesity at ObesityWeek 2026

2d agoGuruFocusBULLISH 64M&A

Eli Lilly Eyes Rhythm Pharmaceuticals (RYTM) in Obesity Sector Acquisition Talks

3d agoSeeking AlphaBULLISH 64M&A

Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR

Rhythm Pharmaceuticals rose 3.6% as traders cited an alert that Eli Lilly submitted a rival bid near $150 per share plus a contingent value right.

3d agoThe FlyBULLISH 74Product/PR

Rhythm: Two-year results from Phase 3 trial showed sustained BMI reductions

3d agoGlobeNewswireBULLISH 64Product/PR

Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026

– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –

3d agoBusiness InsiderBULLISH 63Product/PR

Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026

– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on RYTM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier RYTM move explainers: 2026-11-18 · 2026-11-17 · 2026-11-05